US Dollar Replaced By "Biden Bucks"?
A former advisor to the CIA and Pentagon now believes President Biden plans to retire the US dollar we know.

And replace it with what he calls 'Biden Bucks'. It is underway.
See what Biden signed in Executive Order 14067
Bruce N. Jacobs, insider at Kymera Therapeutics

Bruce N. Jacobs Insider Information

As CFO, Bruce directs financial operations and investor relations for Kymera Therapeutics. Bruce joined Kymera with more than 25 years of experience in health care financial services, investment banking and equity research. He previously was Managing Partner for Westfield Capital Management, a Boston-based equity investment firm. In addition to his core portfolio management responsibilities, he served on the firm’s Management Committee and as the Health Care Team Lead. Bruce was also a Director with Alex Brown & Sons/Deutsche Bank and part of the health care investment banking group and the equity research team. He graduated magna cum laude from the Wharton School of the University of Pennsylvania, earned a Master of Business Administration from the Harvard Business School and is a Chartered Financial Analyst. Bruce is currently a member of the Board of Directors at Boys & Girls Clubs of Boston and serves on the Board of Advisors for Life Science Cares.

What is Bruce N. Jacobs' net worth?

The estimated net worth of Bruce N. Jacobs is at least $61,460.25 as of March 15th, 2021. Mr. Jacobs owns 1,805 shares of Kymera Therapeutics stock worth more than $61,460 as of August 11th. This net worth estimate does not reflect any other investments that Mr. Jacobs may own. Learn More about Bruce N. Jacobs' net worth.

How do I contact Bruce N. Jacobs?

The corporate mailing address for Mr. Jacobs and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected] Learn More on Bruce N. Jacobs' contact information.

Has Bruce N. Jacobs been buying or selling shares of Kymera Therapeutics?

Bruce N. Jacobs has not been actively trading shares of Kymera Therapeutics during the last ninety days. Most recently, Bruce N. Jacobs sold 15,000 shares of the business's stock in a transaction on Wednesday, January 12th. The shares were sold at an average price of $51.85, for a transaction totalling $777,750.00. Learn More on Bruce N. Jacobs' trading history.

Who are Kymera Therapeutics' active insiders?

Kymera Therapeutics' insider roster includes Bruce Booth (Director), Richard Chesworth (Insider), Jared Gollob (Insider), Bruce Jacobs (CFO), and Nello Mainolfi (CEO). Learn More on Kymera Therapeutics' active insiders.

Are insiders buying or selling shares of Kymera Therapeutics?

In the last twelve months, Kymera Therapeutics insiders bought shares 6 times. They purchased a total of 787,233 shares worth more than $21,641,222.82. In the last twelve months, insiders at the sold shares 11 times. They sold a total of 458,985 shares worth more than $26,733,077.98. The most recent insider tranaction occured on May, 26th when Director Bvf Partners L P/Il bought 224,057 shares worth more than $3,183,849.97. Insiders at Kymera Therapeutics own 17.0 % of the company. Learn More about insider trades at Kymera Therapeutics.

Information on this page was last updated on 5/26/2022.

Bruce N. Jacobs Insider Trading History at Kymera Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/12/2022Sell15,000$51.85$777,750.00View SEC Filing Icon  
12/3/2021Sell10,000$53.56$535,600.00View SEC Filing Icon  
9/3/2021Sell10,000$60.12$601,200.00View SEC Filing Icon  
6/3/2021Sell10,000$46.87$468,700.00View SEC Filing Icon  
3/15/2021Sell8,195$60.17$493,093.151,805View SEC Filing Icon  
3/11/2021Sell1,805$60.07$108,426.351,805View SEC Filing Icon  
3/8/2021Sell10,000$50.65$506,500.0010,000View SEC Filing Icon  
See Full Table

Bruce N. Jacobs Buying and Selling Activity at Kymera Therapeutics

This chart shows Bruce N Jacobs's buying and selling at Kymera Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kymera Therapeutics Company Overview

Kymera Therapeutics logo
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $34.05
Low: $31.30
High: $34.48

50 Day Range

MA: $20.82
Low: $14.13
High: $31.43

2 Week Range

Now: $34.05
Low: $13.15
High: $69.12


777,957 shs

Average Volume

599,452 shs

Market Capitalization

$1.76 billion

P/E Ratio


Dividend Yield



A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.